Skip to main content
. 2016 Oct 4;128(20):2415–2422. doi: 10.1182/blood-2016-05-717769

Table 3.

Response rate (≥PR) to therapy based on disease characteristics

Arm B (4 mg)
Arm C (5.5 mg)
Arm B (4 mg)
Arm C (5.5 mg)
Prior bortezomib No prior bortezomib
Response rate 1/9 (11%) 6/12 (50%) 10/26 (38%) 13/23 (57%)
 sCR 0 0 0 1
 CR 0 0 1 0
 VGPR 1 4 6 6
 PR 0 2 3 6
 MR 0 0 5 1
Intermediate or high risk Standard risk
Response rate 1/5 (20%) 3/5 (60%) 10/30 (33%) 16/30 (53%)
 sCR 0 0 0 1
 CR 0 0 1 0
 VGPR 1 1 6 9
 PR 0 2 3 6
 MR 1 0 4 1
Refractory to lenalidomide Not refractory to lenalidomide
Response rate 5/16 (31%) 8/16 (50%) 6/19 (32%) 11/19 (58%)
 sCR 0 1 0 0
 CR 1 0 0 0
 VGPR 2 4 5 6
 PR 2 3 1 5
 MR 3 1 2 0